SG11201405571SA - Indole and indazole compounds that activate ampk - Google Patents

Indole and indazole compounds that activate ampk

Info

Publication number
SG11201405571SA
SG11201405571SA SG11201405571SA SG11201405571SA SG11201405571SA SG 11201405571S A SG11201405571S A SG 11201405571SA SG 11201405571S A SG11201405571S A SG 11201405571SA SG 11201405571S A SG11201405571S A SG 11201405571SA SG 11201405571S A SG11201405571S A SG 11201405571SA
Authority
SG
Singapore
Prior art keywords
indole
indazole compounds
activate ampk
ampk
activate
Prior art date
Application number
SG11201405571SA
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Kimberly O'keefe Cameron
Matthew Scott Dowling
David Christopher Ebner
Dilinie Prasadhini Fernando
Kevin James Filipski
Daniel Wei-Shung Kung
Esther Cheng Yin Lee
Aaron Christopher Smith
Meihua Mike Tu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201405571SA publication Critical patent/SG11201405571SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201405571SA 2012-04-10 2013-04-01 Indole and indazole compounds that activate ampk SG11201405571SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261622129P 2012-04-10 2012-04-10
PCT/IB2013/052604 WO2013153479A2 (en) 2012-04-10 2013-04-01 Indole and indazole compounds that activate ampk

Publications (1)

Publication Number Publication Date
SG11201405571SA true SG11201405571SA (en) 2014-10-30

Family

ID=48237173

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405571SA SG11201405571SA (en) 2012-04-10 2013-04-01 Indole and indazole compounds that activate ampk

Country Status (42)

Country Link
US (2) US8889730B2 (cg-RX-API-DMAC7.html)
EP (1) EP2836490B1 (cg-RX-API-DMAC7.html)
JP (1) JP6026642B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150002782A (cg-RX-API-DMAC7.html)
CN (1) CN104245688A (cg-RX-API-DMAC7.html)
AP (1) AP2014007983A0 (cg-RX-API-DMAC7.html)
AR (1) AR090633A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013246552A1 (cg-RX-API-DMAC7.html)
CA (1) CA2869692C (cg-RX-API-DMAC7.html)
CO (1) CO7091185A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140411A (cg-RX-API-DMAC7.html)
CU (1) CU20140118A7 (cg-RX-API-DMAC7.html)
CY (1) CY1119194T1 (cg-RX-API-DMAC7.html)
DK (1) DK2836490T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000228A (cg-RX-API-DMAC7.html)
EA (1) EA028564B1 (cg-RX-API-DMAC7.html)
EC (2) ECSP14020545A (cg-RX-API-DMAC7.html)
ES (1) ES2637238T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400215A (cg-RX-API-DMAC7.html)
HK (1) HK1202547A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20171028T1 (cg-RX-API-DMAC7.html)
HU (1) HUE033096T2 (cg-RX-API-DMAC7.html)
IL (1) IL234860A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN09200A (cg-RX-API-DMAC7.html)
LT (1) LT2836490T (cg-RX-API-DMAC7.html)
MD (1) MD20140109A2 (cg-RX-API-DMAC7.html)
ME (1) ME02729B (cg-RX-API-DMAC7.html)
MX (1) MX2014012330A (cg-RX-API-DMAC7.html)
NI (1) NI201400121A (cg-RX-API-DMAC7.html)
NZ (1) NZ630700A (cg-RX-API-DMAC7.html)
PE (1) PE20142294A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502280B1 (cg-RX-API-DMAC7.html)
PL (1) PL2836490T3 (cg-RX-API-DMAC7.html)
PT (1) PT2836490T (cg-RX-API-DMAC7.html)
RS (1) RS56290B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201405571SA (cg-RX-API-DMAC7.html)
SI (1) SI2836490T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000420A1 (cg-RX-API-DMAC7.html)
TW (1) TWI465431B (cg-RX-API-DMAC7.html)
UY (1) UY34736A (cg-RX-API-DMAC7.html)
WO (2) WO2013153479A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406792B (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Flap調節劑
WO2014121055A2 (en) 2013-02-04 2014-08-07 Janssen Pharmaceutica Nv Flap modulators
WO2014133008A1 (ja) 2013-02-27 2014-09-04 塩野義製薬株式会社 Ampk活性化作用を有するインドールおよびアザインドール誘導体
CA2905242C (en) * 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
JP6435923B2 (ja) * 2014-03-07 2018-12-12 Jnc株式会社 ジヒドロピラン化合物、液晶組成物および液晶表示素子
CA2959293A1 (en) 2014-08-27 2016-03-03 Shionogi & Co., Ltd. Azaindole derivative having ampk-activating effect
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2016092413A1 (en) * 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
CN107108492B (zh) * 2014-12-24 2021-03-19 北京生命科学研究所 细胞坏死抑制剂
MX386166B (es) 2015-06-18 2025-03-04 89Bio Ltd Derivados de piperidina 1,4-sustituidos.
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
WO2017011917A1 (en) * 2015-07-23 2017-01-26 Thrasos Therapeutics Inc. Methods for treating and preventing polycystic kidney diseases (pkd) using amp-activated protein kinase (ampk) modulators and activators
US10478425B2 (en) 2016-02-26 2019-11-19 Shionogi & Co., Ltd. 5-phenylazaindole derivative having AMPK-activating activity
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
IL289793B2 (en) 2016-04-15 2023-03-01 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
SI3442535T1 (sl) 2016-04-15 2023-01-31 Cancer Research Technology Limited Heterociklične spojine kot zaviralci RET-kinaze
HUE057838T2 (hu) 2016-06-07 2022-06-28 Jacobio Pharmaceuticals Co Ltd SHP2 inhibitorokként hasznos új heterociklusos származékok
WO2018002215A1 (en) 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
HUE056716T2 (hu) 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
SMT202400385T1 (it) 2017-03-23 2024-11-15 Jacobio Pharmaceuticals Co Ltd Nuovi derivati eterociclici utili come inibitori di shp2
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019168874A1 (en) * 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
KR102224550B1 (ko) * 2018-04-02 2021-03-09 울산대학교 산학협력단 신규한 에테르 화합물, 및 광 산화환원 촉매를 이용하여 활성화된 알켄 화합물로부터 에테르 화합물을 제조하는 방법
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN108572223B (zh) * 2018-04-23 2021-01-26 南京明捷生物医药检测有限公司 一种测定多肽中活性诱导物质的方法
TWI825177B (zh) 2018-09-18 2023-12-11 大陸商北京強新生物科技有限公司 非酒精性脂肪性肝病的治療
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
WO2020142547A1 (en) * 2018-12-31 2020-07-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and formulations to treat mitochondrial dysfunction
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
CN112441900B (zh) * 2019-09-05 2024-07-23 浙江中科创越药业有限公司 4-联苯乙酸的制备方法
CN111333486A (zh) * 2020-04-08 2020-06-26 南京优氟医药科技有限公司 一种2-甲基-2-(4-氯苯基)-1,3-丙二醇的生产工艺
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN111423379B (zh) * 2020-05-21 2021-08-03 湖南科技大学 取代3-吲唑类Mcl-1蛋白抑制剂及制备方法和应用
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators
CN116322663A (zh) * 2020-09-30 2023-06-23 比奥维拉迪维治疗股份有限公司 Ampk激活剂及其使用方法
WO2025021039A1 (zh) * 2023-07-21 2025-01-30 深圳众格生物科技有限公司 Ampk激动剂及其用途
WO2025045185A1 (zh) * 2023-08-31 2025-03-06 深圳众格生物科技有限公司 芳基或杂芳基取代的氨基甲酸酯类化合物及其衍生物和用途

Family Cites Families (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965855D1 (en) 1978-09-25 1983-08-18 Farlane Stuart John Mc Pharmaceutical preparations containing a mollusc extract
JP2602037B2 (ja) 1987-10-31 1997-04-23 持田製薬株式会社 1−アシル−2,3−ジヒドロ−4(1h)−キノリノン−4−オキシム誘導体、その製法およびそれらを主成分とする利尿、降圧、抗浮腫および腹水除去用医薬組成物
GB8814277D0 (en) 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
JPH02264757A (ja) 1989-04-06 1990-10-29 Nippon Steel Chem Co Ltd ニトロインドール類の製造方法
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5215994A (en) 1990-09-25 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic derivatives
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
WO1993006082A1 (en) 1991-09-13 1993-04-01 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropyridines
DE4136489A1 (de) 1991-11-06 1993-05-13 Bayer Ag Neue diethylentriamin-derivate und deren verwendung zu diagnostischen und therapeutischen zwecken
TW212798B (cg-RX-API-DMAC7.html) 1991-11-25 1993-09-11 Takeda Pharm Industry Co Ltd
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
EP0597112A4 (en) 1992-03-27 1994-06-22 Kyoto Pharma Ind Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor.
JP3229654B2 (ja) 1992-06-05 2001-11-19 ティーディーケイ株式会社 有機el素子用化合物および有機el素子
CA2116863A1 (en) 1992-07-03 1994-01-20 Sumio Yokota Condensed heterocyclic derivatives and herbicides
GB2271991A (en) 1992-11-02 1994-05-04 Merck Sharp & Dohme N-(2-oxo-1H-1,4-benzodiazepin-3-yl)-ureas
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
CA2183084A1 (en) 1994-02-10 1995-08-17 John Eugene Macor 5-heteroarylindole derivatives
CN1166169A (zh) 1994-07-27 1997-11-26 三共株式会社 用作毒蕈碱性受体别构效应物的杂环化合物
FR2723739B1 (fr) 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
JPH08225535A (ja) 1994-11-15 1996-09-03 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
EP0717143A1 (de) 1994-12-16 1996-06-19 Lignozym GmbH Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
ATE219765T1 (de) 1995-04-10 2002-07-15 Fujisawa Pharmaceutical Co Indolderivate als cgmp-pde inhibitoren
WO1997010214A1 (en) 1995-09-14 1997-03-20 Shionogi & Co., Ltd. Novel phenylacetic acid derivatives and medicinal composition containing the same
JP2000511173A (ja) 1996-05-27 2000-08-29 藤沢薬品工業株式会社 一酸化窒素産生阻害剤としての新規なインドリルおよびベンゾフラニルカルボキサミド
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5861398A (en) 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
WO1998028292A1 (en) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
EP0973767A1 (en) 1997-03-31 2000-01-26 Dupont Pharmaceuticals Company Indazoles of cyclic ureas useful as hiv protease inhibitors
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
WO1999036422A1 (en) 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
SK12752000A3 (sk) * 1998-02-25 2001-03-12 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
EP1077944A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
AU4981199A (en) 1998-07-08 2000-02-01 Gregory N. Beatch Compositions and methods for modulating sexual activity
RU2237663C2 (ru) 1998-07-15 2004-10-10 Тейдзин Лимитед Производное тиобензимидазола и содержащие его фармацевтические композиции
DE19842354A1 (de) 1998-09-16 2000-03-23 Bayer Ag Isothiazolcarbonsäureamide
FR2783520B1 (fr) 1998-09-21 2000-11-10 Oreal Nouveaux 4-hydroxyindoles cationiques, leur utilisation pour la teinture d'oxydation des fibres keratiniques, compositions tinctoriales et procede de teinture
WO2000028993A1 (en) 1998-11-19 2000-05-25 Nortran Pharmaceuticals, Inc. Serotonin ligands as pro-erectile compounds
AR021509A1 (es) 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
CN1105722C (zh) 1999-11-12 2003-04-16 中国科学院上海药物研究所 含氮杂环基的青蒿素衍生物及其制备方法
BR0111034A (pt) 2000-05-22 2003-06-17 Leo Pharma S A Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
WO2001098266A2 (en) 2000-06-20 2001-12-27 Wayne State University N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith
JP2002017387A (ja) 2000-07-06 2002-01-22 Mitsubishi Rayon Co Ltd インドール誘導体の製造法
JP2002017386A (ja) 2000-07-06 2002-01-22 Mitsubishi Rayon Co Ltd インドール−3−カルボン酸誘導体の製造法
WO2002018363A2 (en) 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
DE10046934A1 (de) 2000-09-21 2002-04-18 Consortium Elektrochem Ind Verfahren zur fermentativen Herstellung von nicht-proteinogenen L-Aminosäuren
EP1332141A1 (en) 2000-10-25 2003-08-06 AstraZeneca AB Quinazoline derivatives
EP1381382B1 (en) 2000-11-01 2008-11-26 MERCK PATENT GmbH Methods and compositions for the treatment of diseases of the eye
US6887880B2 (en) 2000-11-20 2005-05-03 Millennium Pharmaceuticals, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof
US6387992B1 (en) 2000-11-27 2002-05-14 Ciba Specialty Chemicals Corporation Substituted 5-heteroaryl-2-(2-hydroxyphenyl)-2h-benzotriazole UV absorbers, a process for preparation thereof and compositions stabilized therewith
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
JP4094955B2 (ja) 2001-01-18 2008-06-04 塩野義製薬株式会社 置換アミノ基を有するテルフェニル化合物
JPWO2002057237A1 (ja) 2001-01-22 2004-05-20 塩野義製薬株式会社 置換アミノ基を有するヘテロ3環化合物
CA2436351A1 (en) 2001-02-02 2002-10-03 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
PL210793B1 (pl) 2001-02-28 2012-03-30 Merck & Co Inc Acylowane pochodne piperydyny
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
GB0106586D0 (en) 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
DK1381590T3 (da) 2001-04-16 2007-10-22 Schering Corp 3,4-disubstituerede cyclobuten-1,2-dioner som CXC-kemokinreceptorligander
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Rhoキナーゼ阻害剤
EP1844771A3 (en) 2001-06-20 2007-11-07 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
JP2004536104A (ja) 2001-07-05 2004-12-02 シナプティック・ファーマスーティカル・コーポレーション Mch選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体
PL207175B1 (pl) 2001-08-01 2010-11-30 Merck Patent Gmbh Zastosowanie inhibitorów integryny do wytwarzania kompozycji farmaceutycznych do zapobiegania i/lub terapii chorób oczu
WO2003020719A1 (en) 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. 1,3-benzothiazinone derivatives and use thereof
US6903131B2 (en) 2001-10-12 2005-06-07 Schering Corporation 3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
WO2003035065A1 (en) 2001-10-26 2003-05-01 Aventis Pharmaceuticals Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
JP2003192716A (ja) 2001-12-27 2003-07-09 Mitsui Chemicals Inc オレフィン重合用触媒および該触媒を用いたオレフィンの重合方法
ES2319753T3 (es) 2002-02-21 2009-05-12 Asahi Kasei Pharma Corporation Derivado del acido fenilalcanoico sustituido y utilizacion del mismo.
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
EP1515716A2 (en) 2002-04-03 2005-03-23 Astrazeneca AB Indole derivatives having anti-angiogenetic activity
JP2005530804A (ja) 2002-05-14 2005-10-13 ベイラー カレッジ オブ メディスン Her2発現の小分子阻害剤
US7008958B2 (en) 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
AU2003281205A1 (en) 2002-07-09 2004-01-23 Fujisawa Pharmaceutical Co., Ltd. Remedy for urinary frequency and urinary incontinence
US6972336B2 (en) 2002-07-18 2005-12-06 Novartis Ag N-alkylation of indole derivatives
AU2003255767A1 (en) 2002-08-10 2004-02-25 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
FR2846656B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004048365A1 (en) 2002-11-21 2004-06-10 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
MXPA05005701A (es) 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil indoles sustituidos en la posicion 3 que tienen afinidad por el receptor de la serotonina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
AU2003303681A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Fused heterocyclic derivates as ppar modulators
US7384965B2 (en) 2003-01-06 2008-06-10 Eli Lilly And Company Fused heterocyclic derivatives as PPAR modulators
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
AU2004213145B2 (en) 2003-02-21 2010-05-13 Chiesi Farmaceutici S.P.A. 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
JP2004284997A (ja) 2003-03-24 2004-10-14 Taoka Chem Co Ltd 高純度インドールカルボン酸類の製造方法
JP2004284998A (ja) 2003-03-24 2004-10-14 Taoka Chem Co Ltd 1−アルキルインドール類の製造方法
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法
DK1615647T3 (da) 2003-04-11 2010-04-06 High Point Pharmaceuticals Llc Farmaceutisk anvendelse af kondenserede 1,2,4-triazoler
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
EP1615637A1 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物
EP1628970A2 (en) 2003-04-30 2006-03-01 The Institutes of Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005005411A1 (en) 2003-07-04 2005-01-20 Glaxosmithkline S.P.A. Substituted indole ligands for the orl-1 receptor
WO2005014554A1 (en) 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
EP1660427A4 (en) 2003-08-14 2006-12-20 Asahi Kasei Pharma Corp SUBSTITUTED ARYLALKANIC DERIVATIVE AND ITS USE
CN1863779B (zh) 2003-10-15 2010-05-05 宇部兴产株式会社 吲唑衍生物
JP4458819B2 (ja) 2003-11-13 2010-04-28 株式会社リコー アゾ置換インドール化合物及びこれを用いた光記録媒体
JP2005145859A (ja) 2003-11-13 2005-06-09 Nippon Steel Chem Co Ltd 脱水素化方法及び芳香族複素環化合物の製造方法
JP4824578B2 (ja) 2003-12-22 2011-11-30 メモリー・ファーマシューティカルズ・コーポレイション インドール類、1,2−ベンズイソオキサゾール類、および1,2−ベンゾイソチアゾール類、ならびにそれらの製造と使用
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
WO2005097203A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Serum protein conjugates of ion channel modulating compounds and uses thereof
JP4510500B2 (ja) 2004-04-15 2010-07-21 株式会社リコー アゾ置換インドール化合物及びアゾ金属キレート化合物、並びに光記録媒体
WO2005111038A2 (en) 2004-05-07 2005-11-24 Memory Pharmaceuticals Corporation 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
ATE437870T1 (de) 2004-05-12 2009-08-15 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ[e]アズレン誘導体及びそれらのアナログ
KR20070024667A (ko) 2004-06-03 2007-03-02 브랜데이스 유니버시티 이작용성 신코나-알칼로이드 기재 촉매를 사용하는 비대칭마이클 및 알돌 부가반응
ATE430132T1 (de) 2004-06-18 2009-05-15 Biolipox Ab Zur behandlung von entzündungen geeignete indole
ZA200610357B (en) 2004-06-18 2008-02-27 Biolipox Ab Indoles useful in the treatment of inflammation
WO2006012504A2 (en) 2004-07-23 2006-02-02 Daiamed, Inc. Compounds and methods for treatment of thrombosis
HRP20120327T1 (hr) 2004-07-28 2012-05-31 Janssen Pharmaceutica Nv Supstituirani indolil alkil amino derivati kao novi inhibitori histonske deacetilaze
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
NZ588431A (en) 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
US20070299114A1 (en) 2004-10-05 2007-12-27 Shionogi & Co., Ltd. Biaryl Derivatives
EP1804801A2 (en) 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
JP2006131519A (ja) 2004-11-04 2006-05-25 Idemitsu Kosan Co Ltd 縮合環含有化合物及びそれを用いた有機エレクトロルミネッセンス素子
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2006051937A1 (ja) 2004-11-15 2006-05-18 Shionogi & Co., Ltd. ヘテロ5員環誘導体
CN101124224A (zh) 2004-12-22 2008-02-13 记忆药物公司 烟碱性α-7受体配体及其制备和用途
JP2008526734A (ja) 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
FR2882054B1 (fr) 2005-02-17 2007-04-13 Sanofi Aventis Sa Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
US7812045B2 (en) 2005-03-30 2010-10-12 Daewoong Pharmaceutical Co., Ltd. Antifungal triazole derivatives
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
RU2382781C2 (ru) 2005-04-22 2010-02-27 Дайити Санкио Компани, Лимитед Гетероциклическое соединение
JP5794721B2 (ja) 2005-05-17 2015-10-14 サーコード バイオサイエンス インコーポレイテッド 眼障害の治療のための組成物および方法
WO2006130437A2 (en) 2005-05-27 2006-12-07 Brandeis University Asymmetric carbon-carbon-bond-forming reactions catalyzed by bifunctional cinchona alkaloids
WO2006130453A1 (en) 2005-05-27 2006-12-07 Brandeis University Asymmetric aldol additions using bifunctional cinchona-alkaloid-based catalysts
US7553964B2 (en) 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
JP2008546651A (ja) 2005-06-14 2008-12-25 メルク フロスト カナダ リミテツド モノアミンオキシダーゼa及びbの可逆的阻害剤
US20080221088A1 (en) 2005-06-23 2008-09-11 Vijay Kumar Potluri 3,4-Substituted Thiazoles as Ampk Activators
KR20080020638A (ko) 2005-06-27 2008-03-05 사노피-아벤티스 β-아드레날린 수용체 키나제 1의 억제제로서의피라졸로피리딘 유도체
AU2006265675A1 (en) 2005-07-04 2007-01-11 Dr. Reddy's Laboratories Ltd. Thiazoles derivatives as AMPK activator
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
EP1754483A1 (en) 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
WO2007022501A2 (en) 2005-08-18 2007-02-22 Microbia, Inc. Useful indole compounds
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
AU2006311851A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-A2 inhibitors
AU2006311765A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
WO2007056281A2 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
KR20080067339A (ko) 2005-11-09 2008-07-18 메모리 파마슈티칼스 코포레이션 1h-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그들의 제조법 및 용도
WO2007058504A1 (en) 2005-11-21 2007-05-24 Lg Life Sciences, Ltd. Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same
CN1978445B (zh) 2005-12-02 2010-09-01 中国科学院上海药物研究所 一种可用作人源腺苷单核苷酸激活蛋白激酶激活剂的化合物及其制备方法和应用
KR20080080173A (ko) 2005-12-14 2008-09-02 브리스톨-마이어스 스큅 컴퍼니 세린 프로테아제 억제제로서 유용한 6-원 헤테로사이클
EA014245B1 (ru) 2005-12-14 2010-10-29 Бристол-Маерс Сквибб Компани Аналоги арилпропионамида, арилакриламида, арилпропинамида или арилметилмочевины в качестве ингибиторов фактора xia
WO2007079173A2 (en) 2005-12-30 2007-07-12 Emergent Biosolutions Inc. Novel 2-heteroaryloxy-phenol derivatives as antibacterial agents
CN101374834B (zh) 2006-02-03 2011-12-14 伊莱利利公司 用于调节fxr的化合物和方法
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
KR20080103584A (ko) 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
CA2644910C (en) 2006-03-31 2014-01-28 Abbott Laboratories Indazole compounds
CN102796086A (zh) 2006-04-18 2012-11-28 雅培制药有限公司 香草素受体亚型1(vr1)的拮抗剂及其用途
PL2463283T3 (pl) 2006-04-20 2014-10-31 Pfizer Prod Inc Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę
ATE529423T1 (de) 2006-05-19 2011-11-15 Abbott Lab Cns-aktivierte kondensierte bi- und heterocyclisch substituierte azabicyklische alkanderivate
AU2007267606A1 (en) 2006-05-24 2007-12-06 Eli Lilly And Company FXR agonists
TW200815398A (en) 2006-06-08 2008-04-01 Ube Industries A novel indazole derivative having spirocyclic structure in the side chain
EP2046741B1 (en) 2006-07-03 2012-10-31 Proximagen Ltd. Indoles as 5-ht6 modulators
FR2903695B1 (fr) 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100826108B1 (ko) 2006-08-04 2008-04-29 한국화학연구원 퓨란-2-카복실산 유도체 및 그의 제조 방법
MX2009001327A (es) 2006-08-07 2009-06-05 Ironwood Pharmaceuticals Inc Compuestos de indol.
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd 1−ピリジン−4−イル−インドール類の製造方法
JP2008106037A (ja) 2006-09-29 2008-05-08 Osaka Prefecture Univ インドール化合物の製造方法およびインドール化合物
WO2008054748A2 (en) 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ATE552262T1 (de) 2006-11-29 2012-04-15 Pfizer Prod Inc Spiroketone als inhibitoren von acetyl-coa- carboxylase
US7825261B2 (en) 2006-12-05 2010-11-02 National Taiwan University Indazole compounds
WO2008072850A1 (en) 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
CA2672167C (en) 2006-12-14 2016-01-26 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors
KR20090100407A (ko) 2006-12-18 2009-09-23 암브룩스, 인코포레이티드 비천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비천연 아미노산 및 폴리펩티드의 용도
JP2010514688A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー インドール−4−イルピリミジニル−2−イル−アミン誘導体およびサイクリン依存性キナーゼ阻害剤としてのその使用
WO2008083124A1 (en) 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US7999001B2 (en) 2007-01-15 2011-08-16 The United States Of America As Represented By The Secretary Of The Army Antiviral compounds and methods of using thereof
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
JP2008179567A (ja) 2007-01-25 2008-08-07 Toray Ind Inc ピラジン誘導体を有効成分とする抗がん剤
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
CN101687789A (zh) 2007-02-12 2010-03-31 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
JP5107589B2 (ja) 2007-02-13 2012-12-26 旭化成株式会社 インドール誘導体
JP2008208074A (ja) 2007-02-27 2008-09-11 Toray Ind Inc ピラジン誘導体を有効成分とする抗がん剤
JP2008222576A (ja) 2007-03-09 2008-09-25 Japan Enviro Chemicals Ltd インドール化合物の製造方法
WO2008110863A1 (en) 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008116910A1 (en) 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
KR20080099174A (ko) 2007-05-07 2008-11-12 주식회사 머젠스 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
AR067770A1 (es) 2007-08-03 2009-10-21 Betagenon Ab Derivados de tiazol y ditiazol para el tratamiento de diabetes
KR20090016804A (ko) 2007-08-13 2009-02-18 주식회사 티지 바이오텍 신규 벤질에스테르계 화합물 및 이를 유효성분으로함유하는 비만, 당뇨 및 고지혈증의 예방 및 치료용 조성물
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
JP5272008B2 (ja) 2007-08-29 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 置換インドール誘導体およびその使用の方法
AR068107A1 (es) 2007-08-29 2009-11-04 Schering Corp Derivados indolicos 2,3 sustituidos y una composicion farmaceutica
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
EP2215075B1 (en) 2007-10-26 2013-12-11 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp inhibitors
US20090124680A1 (en) 2007-10-31 2009-05-14 Mazence Inc. Use of prodrug composition containing naphthoquinone-based compound for manufacture of medicament for treatment or prevention of diseases involving metabolic syndrome
EA019509B1 (ru) 2007-11-16 2014-04-30 Райджел Фармасьютикалз, Инк. Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
WO2009064852A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
JPWO2009084695A1 (ja) 2007-12-28 2011-05-19 カルナバイオサイエンス株式会社 2−アミノキナゾリン誘導体
WO2009096226A1 (ja) 2008-01-31 2009-08-06 National University Corporation Yokohama National University 流体機械
JP5525456B2 (ja) 2008-02-04 2014-06-18 マーキュリー セラピューティクス,インコーポレイテッド Ampk調節因子
WO2009115874A2 (en) 2008-03-17 2009-09-24 Matrix Laboratories Ltd. Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation
CN101977907A (zh) 2008-03-20 2011-02-16 弗·哈夫曼-拉罗切有限公司 吡咯烷基衍生物及其用途
WO2009120783A1 (en) 2008-03-25 2009-10-01 The Johns Hopkins University High affinity inhibitors of hepatitis c virus ns3/4a protease
JP5564033B2 (ja) 2008-03-27 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規インヒビターとしてのアザ−ビシクロヘキシル置換インドリルアルキルアミノ誘導体
HRP20160907T1 (hr) 2008-04-11 2016-09-23 Merck Patent Gmbh Derivati tienopiridona kao aktivatori amp-aktivirane protein kinaze (ampk)
AU2009240643B2 (en) 2008-04-23 2014-03-06 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
MX2010011916A (es) 2008-05-05 2010-11-26 Merck Patent Gmbh Derivados de tienopiridonas como activadores de proteinas cinasa activados por amp (ampk).
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
US20110009443A1 (en) 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
SI2285786T1 (sl) 2008-06-16 2014-02-28 Merck Patent Gmbh Derivati kinoksalindiona
US8217028B2 (en) 2008-06-20 2012-07-10 Glaxo Group Limited 1,2,4-oxadiazole indole compounds
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
EP2300496A4 (en) 2008-07-16 2012-04-25 King Pharmaceuticals Res & Dev ATHEROSCLEROSIS TREATMENT METHODS
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
US20110130365A1 (en) 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls
AP2728A (en) 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
WO2010036910A1 (en) 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
CA2736472A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2012507530A (ja) 2008-10-29 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病剤である新規な環状ベンズイミダゾール誘導体
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010056041A2 (ko) 2008-11-13 2010-05-20 주식회사 머젠스 허혈 또는 허혈 재관류에 의해 유발되는 심장질환의 치료 및 예방을 위한 약제 조성물
MX2011005221A (es) 2008-11-21 2011-08-03 Raqualia Pharma Inc Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b.
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
US20110237633A1 (en) 2008-12-11 2011-09-29 Bijoy Panicker Small molecule modulators of hepatocyte growth factor (scatter factor) activity
JP5855942B2 (ja) 2008-12-18 2016-02-09 メルク セローノ ソシエテ アノニム 多発性硬化症の治療に有用なオキサジアゾール縮合複素環式誘導体
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
CN104803986A (zh) 2008-12-23 2015-07-29 哈佛大学校长及研究员协会 坏死性凋亡的小分子抑制剂
MX2011007639A (es) 2009-01-28 2011-09-15 Rigel Pharmaceuticals Inc Compuestos de carboxamida y metodos para usar los mismos.
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
US20100210682A1 (en) 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
WO2010103438A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
ES2427279T3 (es) 2009-03-11 2013-10-29 Pfizer Inc. Derivados de benzofuranilo usados como inhibidores de glucocinasa
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
ES2527046T3 (es) 2009-03-24 2015-01-19 Sumitomo Chemical Company, Limited Método para la preparación de un compuesto de éster del ácido borónico
DK2607348T3 (da) 2009-03-31 2021-05-25 Renascience Inc Inhibitor af plasminogenaktivatorinhibitor-1
US8927576B2 (en) 2009-04-06 2015-01-06 PTC Therpeutics, Inc. HCV inhibitor and therapeutic agent combinations
CA2759891A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
WO2010128425A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
EP2438051A1 (en) 2009-06-05 2012-04-11 Pfizer Inc. L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
NZ597075A (en) 2009-07-08 2013-03-28 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
WO2011014128A1 (en) 2009-07-30 2011-02-03 National University Of Singapore Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
GB0915892D0 (en) 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
WO2011032320A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP2013047189A (ja) 2009-12-25 2013-03-07 Kyorin Pharmaceutical Co Ltd 新規パラバン酸誘導体及びそれらを有効成分とする医薬
CN102803269B (zh) 2009-12-29 2016-01-13 珀科赛尔 Ampk的噻吩并[2,3-b]嘧啶二酮活化剂及其治疗用途
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8796254B2 (en) 2010-03-31 2014-08-05 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
US8344137B2 (en) 2010-04-14 2013-01-01 Hoffman-La Roche Inc. 3,3-dimethyl tetrahydroquinoline derivatives
JP2013525466A (ja) 2010-05-05 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ampkのアクチベーターとして用いられるピロロ[3,2−d]ピリミジン−3−イル誘導体
US8592594B2 (en) 2010-07-02 2013-11-26 Hoffmann-La Roche Inc. Tetrahydro-quinoline derivatives
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
KR101190141B1 (ko) 2010-08-24 2012-10-12 서울대학교산학협력단 Ampk를 활성화시키는 화합물을 함유하는 약학조성물
JP2013230986A (ja) 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
WO2012027548A1 (en) 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Compounds and methods for prevention and treatment of alzheimer's and other diseases
AU2011299894B2 (en) 2010-09-10 2015-08-06 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having AMPK activating effect
WO2012040499A2 (en) 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
US8546427B2 (en) 2010-10-20 2013-10-01 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
US8809369B2 (en) 2011-01-26 2014-08-19 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2683720A1 (en) 2011-03-07 2014-01-15 GlaxoSmithKline LLC 1H-PYROLLO[3,2-d]PYRIMIDINEDIONE DERIVATIVES
CN103517896B (zh) 2011-03-07 2016-09-21 葛兰素史密斯克莱有限责任公司 喹啉酮衍生物
CN103889976A (zh) 2011-08-12 2014-06-25 弗·哈夫曼-拉罗切有限公司 吲唑化合物、组合物及使用方法
GEP20166489B (en) 2012-02-21 2016-06-10 Acraf 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Also Published As

Publication number Publication date
UY34736A (es) 2013-11-29
PE20142294A1 (es) 2014-12-27
WO2013153479A3 (en) 2013-12-05
TW201402547A (zh) 2014-01-16
LT2836490T (lt) 2017-08-10
EP2836490B1 (en) 2017-06-14
EP2836490A2 (en) 2015-02-18
HUE033096T2 (en) 2017-11-28
ME02729B (me) 2017-10-20
ZA201406792B (en) 2016-01-27
MD20140109A2 (ro) 2015-02-28
TWI465431B (zh) 2014-12-21
US8889730B2 (en) 2014-11-18
CU20140118A7 (es) 2014-11-27
PH12014502280A1 (en) 2014-12-15
CA2869692C (en) 2016-08-02
AU2013246552A1 (en) 2014-09-25
HK1202547A1 (en) 2015-10-02
DOP2014000228A (es) 2014-11-30
IN2014DN09200A (cg-RX-API-DMAC7.html) 2015-07-10
EA201491592A1 (ru) 2015-03-31
RS56290B1 (sr) 2017-12-29
MX2014012330A (es) 2015-01-12
PH12014502280B1 (en) 2014-12-15
JP6026642B2 (ja) 2016-11-16
CO7091185A2 (es) 2014-10-21
AR090633A1 (es) 2014-11-26
WO2014140704A1 (en) 2014-09-18
KR20150002782A (ko) 2015-01-07
SI2836490T1 (sl) 2017-08-31
PT2836490T (pt) 2017-08-23
WO2013153479A2 (en) 2013-10-17
ECSP14020545A (es) 2017-07-31
JP2015512931A (ja) 2015-04-30
AP2014007983A0 (en) 2014-10-31
CN104245688A (zh) 2014-12-24
TN2014000420A1 (fr) 2016-03-30
EA028564B1 (ru) 2017-12-29
NZ630700A (en) 2015-11-27
CY1119194T1 (el) 2018-02-14
CR20140411A (es) 2014-10-14
IL234860A0 (en) 2014-12-31
ES2637238T3 (es) 2017-10-11
ECSP14026271A (es) 2015-11-30
GT201400215A (es) 2015-10-15
NI201400121A (es) 2015-03-05
HRP20171028T1 (hr) 2017-10-06
PL2836490T3 (pl) 2017-10-31
CA2869692A1 (en) 2013-10-17
US20130267493A1 (en) 2013-10-10
DK2836490T3 (en) 2017-07-31
US20150038484A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
IL234860A0 (en) Indole and indole compounds which activate ampk
EP2838881A4 (en) ISO-INDOLONE DERIVATIVES
EP2875959A4 (en) PRINTING MACHINE AND TABLET ASSOCIATED
AU343431S (en) Connecting device
ZA201406579B (en) Tetrahydro-quinazolinone derivates as tank and parp inhibitors
IL243728B (en) rorc2-inhibiting indole derivatives and their uses
GB201317425D0 (en) Bedding system
GB201218512D0 (en) Property managment system
SG11201500119QA (en) Deluge system
EP2885291A4 (en) INHIBITORS OF VEGFR3
EP2837623A4 (en) NEW 1-SUBSTITUTED INDAZONE DERIVATIVE
EP2885292A4 (en) VEGFR3 INHIBITORS
GB2502122B (en) Amplifier
PL2626491T3 (pl) Układ okuć
GB201214990D0 (en) Disaster prevention device
GB201217285D0 (en) Indole derivatives
PL2634424T3 (pl) Sposób budowania fundamentu dla konstrukcji podobnej do wieży
GB2494023B (en) Trailer
GB201203879D0 (en) Pack-a-truck trailer
GB2501945B (en) Deluge system
GB2510757B (en) Deluge system
GB2488447B (en) Trailer
GB201322950D0 (en) Transportation device
GB201211372D0 (en) Amplifier circuits
AU5123P (en) Sprilecstar Cordyline banksii